Compare Jabil Inc (JBL) vs Revvity Inc (RVTY) Price & Performance

JBL trades at $368.37, up 9.43% with strong bullish momentum driven by AI infrastructure demand and recent earnings beats. The stock shows robust technical strength with moving averages signaling buy and price approaching resistance at $371. Fundamentally, revenue growth accelerated to $33.6B in 2026 with net profit margin improving to 2.56%, though valuation multiples remain elevated with P/E at 44.63.

Outlook remains positive with analyst consensus target of $448.29 (22% upside) and 50% buy ratings. Key opportunities include projected AI revenue growth to $20B+ by 2027, while risks include competitive pressures and the stock's premium valuation. Recent UBS upgrade to Buy highlights multi-year AI growth cycle potential.

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.